Therapeutic Value of Small Molecule Inhibitor to Plasminogen Activator Inhibitor–1 for Lung Fibrosis
- 1 January 2012
- journal article
- Published by American Thoracic Society in American Journal of Respiratory Cell and Molecular Biology
- Vol. 46 (1), 87-95
- https://doi.org/10.1165/rcmb.2011-0139oc
Abstract
Fibrosis is a final stage of many lung diseases, with no effective treatment. Plasminogen activator inhibitor-1 (PAI-1), a primary inhibitor of tissue-type and urokinase-type plasminogen activators (tPA and uPA, respectively), plays a critical role in the development of fibrosis. In this study, we explored the therapeutic potential of an orally effective small molecule PAI-1 inhibitor, TM5275, in a model of lung fibrosis induced by transforming growth factor-β1 (TGF-β1), the most potent and ubiquitous profibrogenic cytokine, and in human lung fibroblasts (CCL-210 cells). The results show that an intranasal instillation of AdTGF-β1(223/225), an adenovirus expressing constitutively active TGF-β1, increased the expression of PAI-1 and induced fibrosis in murine lung tissue. On the other hand, treating mice with 40 mg/kg of TM5275 for 10 days, starting 4 days after the instillation of AdTGF-β1(223/225), restored the activities of uPA and tPA and almost completely blocked TGF-β1-induced lung fibrosis, as shown by collagen staining, Western blotting, and the measurement of hydroxyproline. No loss of body weight was evident under these treatment conditions with TM5275. Furthermore, we show that TM5275 induced apoptosis in both myofibroblasts (TGF-β1-treated) and naive (TGF-β1-untreated) human lung fibroblasts, and this apoptosis was associated with the activation of caspase-3/7, the induction of p53, and the inhibition of α-smooth muscle actin, fibronectin, and PAI-1 expression. Such an inhibition of fibrotic responses by TM5275 occurred even in cells pretreated with TGF-β1 for 6 hours. Together, the results suggest that TM5275 is a relatively safe and potent antifibrotic agent, with therapeutic potential in fibrotic lung disease.Keywords
This publication has 54 references indexed in Scilit:
- Increased transforming growth factor beta 1 expression mediates ozone-induced airway fibrosis in miceInhalation Toxicology, 2011
- Oxidative Modification of Nuclear Mitogen-activated Protein Kinase Phosphatase 1 Is Involved in Transforming Growth Factor β1-induced Expression of Plasminogen Activator Inhibitor 1 in FibroblastsOnline Journal of Public Health Informatics, 2010
- SPARC Suppresses Apoptosis of Idiopathic Pulmonary Fibrosis Fibroblasts through Constitutive Activation of β-CateninOnline Journal of Public Health Informatics, 2010
- A Novel Inhibitor of Plasminogen Activator Inhibitor-1 Provides Antithrombotic Benefits Devoid of Bleeding Effect in Nonhuman PrimatesJournal of Cerebral Blood Flow & Metabolism, 2010
- Plasminogen Activation–Induced Pericellular Fibronectin Proteolysis Promotes Fibroblast ApoptosisAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- Glutathione suppresses TGF-β-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoterAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Essential role of p53 in silica-induced apoptosisAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2005
- Protease Nexin-1 Inhibits Plasminogen Activation-induced Apoptosis of Adherent CellsOnline Journal of Public Health Informatics, 2004
- Idiopathic Pulmonary FibrosisDrugs, 2004
- A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 1999